Patents Assigned to Ablynx N.V.
  • Serum albumin binding proteins
    Patent number: 9573992
    Abstract: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: February 21, 2017
    Assignee: Ablynx N.V.
    Inventors: Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken
  • Method for the production of immunoglobulin single variable domains
    Patent number: 9534039
    Abstract: Methods are provided for the expression of immunoglobulin variable domains that are secreted into the culture medium. The methods provide for the production of homogeneous immunoglobulin variable domains in which the proportion of product-related variants that comprise, at the N-terminus, at least one redundant amino acid residue derived from the secretion signal is strongly reduced or absent.
    Type: Grant
    Filed: May 9, 2012
    Date of Patent: January 3, 2017
    Assignee: Ablynx N.V.
    Inventors: Ann Brigé, Peter Schotte, Bart Walcarius
  • Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
    Patent number: 9534055
    Abstract: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: December 11, 2013
    Date of Patent: January 3, 2017
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Sigrid Cornelis, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • AMINO ACID SEQUENCES DIRECTED AGAINST THE ANGIOPOIETIN/TIE SYSTEM AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF DISEASES AND DISORDERS RELATED TO ANGIOGENESIS
    Publication number: 20160368978
    Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.
    Type: Application
    Filed: May 18, 2016
    Publication date: December 22, 2016
    Applicant: Ablynx N.V.
    Inventors: MARIA GONZALEZ PAJUELO, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
  • Amino acid sequences directed against GPCRS and polypeptides comprising the same for the treatment of GPCR-related diseases and disorders
    Patent number: 9512236
    Abstract: The present invention relates to amino acid sequences that are directed against G-protein coupled receptors (GPCRs), as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: October 12, 2012
    Date of Patent: December 6, 2016
    Assignee: Ablynx N.V.
    Inventors: Hendrik Adams, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Christophe Blanchetot, Martine Smit, Regorius Leurs, Sven Jähnichen, Peter Vanlandschoot, Francis Descamps, Maria Gonzalez Pajuelo, Pascal Gerard Merchiers, Catelijne Stortelers, Philippe Van Rompaey, David Andre Baptiste Maussang-Detaille, Maarten Van Roy
  • Inhibition of bone resorption with RANKL binding peptides
    Patent number: 9505840
    Abstract: Methods are provided for inhibiting bone resorption and/or osteoclast activity. More specifically, methods are provided wherein polypeptides against RANK-L are administered to a subject less frequently and/or at lower dose, while still maintaining effective inhibition of bone resorption and/or osteoclast activity in the subject at unexpectedly prolonged periods of time, particularly in view of the doses administered.
    Type: Grant
    Filed: May 29, 2012
    Date of Patent: November 29, 2016
    Assignee: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Alex Hemeryck
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS
    Publication number: 20160333099
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: February 12, 2016
    Publication date: November 17, 2016
    Applicant: Ablynx N.V.
    Inventors: ELS ANNA ALICE BEIRNAERT, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • Amino acid sequences directed against RANK-L and polypeptides comprising the same for the treatment of bone diseases and disorders
    Patent number: 9475877
    Abstract: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: September 11, 2009
    Date of Patent: October 25, 2016
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Sigrid Cornelis, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • Method for producing solid formulations comprising immunoglobulin single variable domains
    Patent number: 9468679
    Abstract: Methods for preparing solid formulations of immunoglobulin single variable domains are provided. The methods are based on contacting solid carrier(s) with a liquid comprising the immunoglobulin single variable domains, e.g. by spraying the liquid onto the solid carrier(s), to cause granulation or coating of the carrier(s). During contacting the carrier is agitated, e.g. in a fluid bed, and the mixture of carrier and liquid is exposed to heat, e.g. a heated air stream, to evaporate the liquid.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: October 18, 2016
    Assignee: Ablynx N.V.
    Inventors: Ann Debunne, Veronique De Brabandere
  • Method for the production of domain antibodies
    Patent number: 9464138
    Abstract: The present invention relates to a method for producing a domain antibody in a yeast, wherein the formation of disulfide bridges in the domain antibody is promoted. The method encompasses the addition of oxidizing agents, preferably oxidizing metal ions, preferably one or more selected from Cu2+, Fe2+, Fe3+ and Zn2+.
    Type: Grant
    Filed: April 30, 2010
    Date of Patent: October 11, 2016
    Assignee: Ablynx N.V.
    Inventors: Peter Schotte, Patrick Stanssens, Christine Labeur, Jean-Luc Jonniaux, Marc Jozef Lauwereys
  • AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
    Publication number: 20160289327
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: February 23, 2016
    Publication date: October 6, 2016
    Applicant: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • STABLE FORMULATIONS OF POLYPEPTIDES AND USES THEREOF
    Publication number: 20160279242
    Abstract: Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from polysorbate 80, polysorbate 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.
    Type: Application
    Filed: February 12, 2016
    Publication date: September 29, 2016
    Applicant: Ablynx N.V.
    Inventors: ANN BRIGE, Christine Labeur, Veronique De Brabandere, Marc Jozef Lauwereys
  • AMINO ACID SEQUENCES THAT MODULATE THE INTERACTION BETWEEN CELLS OF THE IMMUNE SYSTEM
    Publication number: 20160280786
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: February 23, 2016
    Publication date: September 29, 2016
    Applicant: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Hans De Haard, Renee de Bruin
  • METHOD FOR GENERATION OF IMMUNOGLOBULIN SEQUENCES
    Publication number: 20160264664
    Abstract: The present invention relates to a method for generating immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored. The invention also provides immunoglobulin sequences obtainable by the method of the invention. Specifically, the present invention relates to the generation of immunoglobulin sequences by use of DNA vaccination. More specifically, the present invention relates to generation of immunoglobulin sequences in camelids, preferably directed against cell-associated antigens, in particular antigens with multiple transmembrane spanning domains, including GPCRs and ion channels, by DNA vaccination. Furthermore, the present invention relates to said immunoglobulin sequences against cell-associated antigens, more particularly, antigens that are membrane-anchored, such as e.g. GPCRs and ion channels, more preferably ion channels.
    Type: Application
    Filed: February 10, 2016
    Publication date: September 15, 2016
    Applicant: Ablynx N.V.
    Inventors: Toon Laeremans, Catelijne Stortelers, Friedrich Nolte, Maria Gonzalez Pajuelo, Joana Assunção, Philippe Van Rompaey
  • FORMULATIONS OF SINGLE DOMAIN ANTIGEN BINDING MOLECULES
    Publication number: 20160263220
    Abstract: The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.
    Type: Application
    Filed: February 11, 2016
    Publication date: September 15, 2016
    Applicant: Ablynx N.V.
    Inventors: JASON E. FERNANDEZ, Daniel A. Dixon, Andrea Paulson
  • BISPECIFIC NANOBODIES
    Publication number: 20160251440
    Abstract: The present disclosure relates to bispecific polypeptides comprising a first and a second immunoglobulin single variable domain (ISV), wherein said first ISV binds to a first target on the surface of a cancer cell with a low affinity and, when bound inhibits a function of said first target, and a said second ISV binds to a second target on the surface of said cell with a high affinity and wherein said first target is different from said second target. The present invention further discloses methods for identifying and making the same.
    Type: Application
    Filed: September 26, 2014
    Publication date: September 1, 2016
    Applicant: Ablynx N.V.
    Inventors: Annelies Roobrouck, Catelijne Stortelers, Peter Vanlandschoot, Stephanie Staelens, Miguel Conde, Hugo Soares, Dominique Schols
  • Formulations of single domain antigen binding molecules
    Patent number: 9393304
    Abstract: The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.
    Type: Grant
    Filed: October 29, 2009
    Date of Patent: July 19, 2016
    Assignee: Ablynx N.V.
    Inventors: Jason E. Fernandez, Daniel A. Dixon, Andrea Paulson
  • Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
    Patent number: 9382333
    Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl2, Angptl3, Angptl4, Angptl5, Angptl6, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: July 5, 2016
    Assignee: Ablynx N.V.
    Inventors: Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
  • Single domain antibodies directed against tumor necrosis factor-alpha and uses therefor
    Patent number: 9371381
    Abstract: The present invention relates to polypeptides derived from single domain heavy chain antibodies directed to Tumor Necrosis Factor-alpha. It further relates to single domain antibodies that are Camelidae VHHs. It further relates to methods of administering said polypeptides. It further relates to protocols for screening for agents that modulate the TNF-alpha receptor, and the agents resulting from said screening.
    Type: Grant
    Filed: October 31, 2014
    Date of Patent: June 21, 2016
    Assignee: Ablynx, N.V.
    Inventors: Karen Silence, Marc Jozef Lauwereys, Hans De Haard
  • AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASES
    Publication number: 20160152693
    Abstract: The present invention relates in part to amino acid sequences that are directed against and/or that can specifically bind to an envelope protein of a virus, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: October 29, 2015
    Publication date: June 2, 2016
    Applicant: Ablynx N.V.
    Inventors: Catelijne Stortelers, Peter Vanlandschoot, Erik Depla, Jose Melero